Evidence map›Paper›PMID 29328905›Full record

ReviewBlood transfusion = Trasfusione del sangue2018

Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management.

Gary Benson, Günter Auerswald, Gerry Dolan, Anne Duffy, Cedric Hermans, Rolf Ljung, Massimo Morfini, Silva Zupančić Šalek

Open access · greenAbstract readReview
In one paragraph

Review in Blood transfusion = Trasfusione del sangue, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Emicizumab for the treatment of haemophilia A: a narrative review.Blood transfusion = Trasfusione del sangue · 2019
    Pooled it
  3. Trial
  4. Trial
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 7 countries.

Gary BensonHaemophilia and Thrombosis Centre, Belfast City Hospital, Belfast, Northern Ireland, United Kingdom.
Günter AuerswaldKlinikum Bremen-Mitte, Professor Hess Children's Hospital, Bremen, Germany.
Gerry DolanCentre for Haemostasis and Thrombosis, St Thomas' Hospital, London, United Kingdom.
Anne DuffyWFH Psychosocial Committee, Irish Haemophilia Society, Dublin, Ireland.
Cedric HermansHaemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Rolf LjungDepartment of Paediatrics, Lund University, Lund, Sweden.
Massimo MorfiniItalian Association of Haemophilia Centres, Florence, Italy.
Silva Zupančić ŠalekMedical School University of Zagreb, Zagreb, Croatia.
Cliniques Universitaires Saint-Luc · BEIrish Cancer Society · IEItalian Society of Physiotherapy · ITKlinikum Bremen-Mitte · DELund University · SESt Thomas' Hospital · GBUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mild haemophilia is defined by factor levels between 0.05 and 0.40 IU/mL and is characterised by traumatic bleeds. Major issues associated with mild haemophilia are that it may not present for many years after birth, and that awareness, even within families, may be low. Methodological problems exist in diagnosis, such as inconsistencies in results obtained from different assays used to measure factor levels in mild haemophilia. Advances in genetic testing provide insight into diagnosis as well as the likelihood of inhibitor development, which is not uncommon in patients with mild or moderate haemophilia and can increase morbidity. The management of patients with mild haemophilia is a challenge. This review includes suggestions around formulating treatment plans for these patients, encompassing the full spectrum from clinical care of the newly diagnosed neonate to that of the ageing patient with multiple comorbidities. Management strategies consider not only the vast differences in these patients' needs, but also risks of inhibitor development and approaches to optimally engage patients.

Indexed as

Blood Coagulation Factor InhibitorsBlood Coagulation FactorsGuidelines as TopicHemophilia AHumansBlood Coagulation Factor InhibitorsBlood Coagulation Factors

Identifiers

PMID29328905
PMCPMC6214819
OpenAlexW2911551961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.